Rounds 1 & 2 | Round 3 | Total | |
---|---|---|---|
All patients | (N = 306) | (N = 131) | (N = 437) |
Sex – male, n (%) | 204 (66.7) | 85 (64.9) | 289 (66.1) |
Age (years) – mean (SD) | 66.4 (10.9) | 64.3 (11.3) | 65.8 (11.1) |
≥ 65 years, n (%) | 189 (61.8) | 69 (52.7) | 258 (59.0) |
≥ 75 years, n (%) | 73 (23.9) | 27 (20.6) | 100 (22.9) |
Patients receiving concurrent oxaliplatina | (N = 85) | (N = 71) | (N = 156) |
Sex – male, n (%) | 65 (76.5) | 49 (69.0) | 114 (73.1) |
Age (years) – mean (SD) | 63.8 (11.2) | 63.6 (10.1) | 63.7 (10.6) |
≥ 65 years, n (%) | 48 (56.5) | 33 (46.5) | 81 (51.9) |
≥ 75 years, n (%) | 15 (17.6) | 10 (14.1) | 25 (16.0) |